Inventiva SA
PAR:IVA

Watchlist Manager
Inventiva SA Logo
Inventiva SA
PAR:IVA
Watchlist
Price: 2.885 EUR -2.04% Market Closed
Market Cap: 434.1m EUR

Net Margin
Inventiva SA

-2 002.7%
Current
-1 009%
Average
-6.8%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 002.7%
=
Net Income
-184.2m
/
Revenue
9.2m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
FR
Inventiva SA
PAR:IVA
434.1m EUR
-2 003%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
328.7B USD
7%
US
Amgen Inc
NASDAQ:AMGN
155B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
137B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.6B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
119.6B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
53B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.7B USD
-11%

Inventiva SA
Glance View

Market Cap
434.1m EUR
Industry
Biotechnology

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

IVA Intrinsic Value
0.927 EUR
Overvaluation 68%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 002.7%
=
Net Income
-184.2m
/
Revenue
9.2m
What is the Net Margin of Inventiva SA?

Based on Inventiva SA's most recent financial statements, the company has Net Margin of -2 002.7%.

Back to Top